The patient Wu completed treatment and was discharged from Tongji Hospital. [Photo provided to chinadaily.com.cn]
The 63rd American Society of Hematology Annual Meeting was successfully held on Dec 11-14, 2021. The meeting reported a series of newest breakthroughs in chimeric antigen receptor T-cell therapy. The five-year follow-up data updates of the single-arm phase II ZUMA-1 trial showed that the five-year overall survival rate was 42.6 percent among patients that have received CAR-T cell therapy. In recent years, CAR-T cell therapy has achieved great success in the field of lymphoma.
It is even challenging the supremacy of autologous stem-cell transplantation, which has been a key course of treatment for lymphoma in the past few decades. However, both ASCT and CAR-T have limitations. Many studies have indicated that CAR-T therapy and hematopoietic stem-cell transplantation have a complementary effect when used together, and can achieve better efficacy. For example, patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have achieved better survival benefits after receiving ASCT combined with CAR-T therapy.
What benefits will be achieved with the combination of ASCT and CAR-T therapy?
ASCT is currently a critical treatment for lymphoma, but what would the efficacy be if it is combined with the promising CAR-T therapy?
Professor Zhou Jianfeng, director of the Department of Hematology at Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, together with his team members, has applied the innovative combination of traditional autologous hematopoietic stem-cell transplantation with CAR-T therapy to the treatment of relapsed and refractory lymphoma.
The results of this groundbreaking clinical study were published last August in the core global hematology journal "Transplantation and Cellular Therapy". The study indicated that lymphoma develops a complex immunosuppressive microenvironment, which may prevent CAR-T from continuously targeting tumors. However, autologous hematopoietic stem-cell transplantation combined with high-dose chemotherapy can help CAR-T overcome this immunosuppressive microenvironment and promote the proliferation of CAR T-cells, thereby precisely killing cancer.
For lymphoma affecting the central nervous system in particular, the Department of Hematology of Tongji Hospital has led another clinical trial, specifically targeting in the long-term cure of patients in advanced stages and with CNS invasion after receiving the combined treatment of autologous hematopoietic stem-cell transplantation and CAR-T for the first time in the world. The results were published in the globally authoritative journal "Blood Cancer Journal". These results have received unanimous acclaim from medical institutions both at home and abroad and have drawn widespread attention. Subsequently, its efficacy and safety have been confirmed in many well-known blood disease centers.
In the past few decades, autologous hematopoietic stem-cell transplantation has played a fundamental role in the treatment of lymphoma. Therefore, the medical community expects that the combination of ASCT and CAR-T can bring more treatment options and benefits to patients with lymphoma.
Case sharing: Combination of ASCT and CAR-T therapy improves CNS lymphoma patient survival benefits
On Dec 21, Wu, a 52 years old woman, who suffered from DLBCL with multiple parts of the brain affected, received autologous hematopoietic stem-cell transplantation combined with CAR-T therapy at Tongji Hospital of Huazhong University of Science and Technology. She has since been discharged successfully.
Chief physician Meng Fankai, a member of the Tongji CAR-T therapy team, said, "As a typical case of lymphoma involving the central nervous system, Wu received six cycles of chemotherapy in the local hospital and developed memory impairment. She had tried alternative treatments, but with her condition deteriorating, she couldn't even recognize her family."
After a detailed evaluation, the team from the Department of Hematology of Tongji Hospital decided to adopt autologous hematopoietic stem-cell transplantation combined with CAR-T therapy for Wu. They collected stem cells and concurrently performed high-dose chemotherapy. After that, they infused autologous hematopoietic stem cells combined with sequential infusion of CAR T-cells. Wu's disease was quickly brought under effective control, and her cognitive abilities gradually returned to normal.
Professor Zhou Jianfeng said that autologous hematopoietic stem-cell transplantation can effectively break the immune barrier, help CAR-T drugs enter immune exempt organs, and offer precise efficacy. With large-scale promotion and application of this therapy in the future, it will be possible to offer new options to save patients suffering from lymphoma.
However, R/R DLBCL is still a common clinically challenging problem, especially in patients with refractory relapses that involve the CNS. With proper and personalized pretreatment for tumor reduction and effective control of the disease in the CNS, patients with CNS involvement are no longer problem in CAR T-cell therapy. Moreover, autologous transplantation combined with CAR T-cell therapy has a high complete remission rate, and the depth of remission is better than that of CAR T-cell therapy alone.
After receiving autologous transplantation combined with CAR-T therapy, patients with CNS involvement may overcome adverse prognostic factors and achieve good efficacy. The medical community is continuing to explore new treatments and strategies, hoping to improve the cure rate, prolong the survival period, and solve refractory recurrence through the application of individualized and precise treatments for different patients.
Read the original here:
CAR-T cell therapy with ASCT brings hope to lymphoma patients - Chinadaily USA
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
- Sight Care Reviews - Overpriced or Worth the Hype? SightCare Pills ... - Journal of the San Juan Islands - November 9th, 2023
- 6 Amazing Health Benefits Of Giloy (Tinospora cordifolia) - WION - November 9th, 2023
- The Global Market for Bispecific Antibody Therapeutics Contract Manufacturing 2023-2030: Driven by Demand for Innovative Therapies and Promising... - November 7th, 2023
Recent Comments